




RealRate

PHARMACEUTICAL 2016

Karyopharm Therapeutics Inc
Rank 82 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Karyopharm Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karyopharm Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 128% points. The greatest weakness of Karyopharm Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 349%, being 86% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	177,600
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,132
Liabilities, Non-Current	0
Other Assets	34,360
Other Compr. Net Income	-253
Other Expenses	0
Other Liabilities	1,946
Other Net Income	895
Other Revenues	250
Property and Equipment	3,483
Research and Development	97,744
Selling, General and Administrative Expense	21,582

Output Variable	Value in 1000 USD
Assets	215,443
Liabilities	17,078
Expenses	119,326
Revenues	250
Stockholders Equity	198,365
Net Income	-118,181
Comprehensive Net Income	-118,308
BaseVar	176,622
ECR before Limited Liability	270%
Economic Capital Ratio	349%